Clinicopathological, genomic and immunological factors in colorectal cancer prognosis.

about

Integration of stereotactic radiotherapy in the treatment of metastatic colorectal cancer patients: a real practice study with long-term outcome and prognostic factors

P2860

Q59133181-137D08AB-958A-447A-8DDB-A4208E228E2C

P2860

Clinicopathological, genomic and immunological factors in colorectal cancer prognosis.

Item

http://www.wikidata.org/entity/Q47728264

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Clinicopathological, genomic and immunological factors in colorectal cancer prognosis.

@en

Clinicopathological, genomic and immunological factors in colorectal cancer prognosis.

@en-gb

Clinicopathological, genomic and immunological factors in colorectal cancer prognosis.

@nl

type

Item

label

Clinicopathological, genomic and immunological factors in colorectal cancer prognosis.

@en

Clinicopathological, genomic and immunological factors in colorectal cancer prognosis.

@en-gb

Clinicopathological, genomic and immunological factors in colorectal cancer prognosis.

@nl

prefLabel

Clinicopathological, genomic and immunological factors in colorectal cancer prognosis.

@en

Clinicopathological, genomic and immunological factors in colorectal cancer prognosis.

@en-gb

Clinicopathological, genomic and immunological factors in colorectal cancer prognosis.

@nl

P1154

2-s2.0-85040718456

http://www.w3.org/2001/XMLSchema#string

P1433

British Journal of Surgery

P1476

Clinicopathological, genomic and immunological factors in colorectal cancer prognosis.

@en

P2093

K M Marks

http://www.w3.org/2001/XMLSchema#string

N P West

http://www.w3.org/2001/XMLSchema#string

P2860

MicroRNAs: target recognition and regulatory functions

Microsatellite instability in colorectal cancer

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

The immune contexture in human tumours: impact on clinical outcome

Risk of metachronous colorectal cancer following colectomy in Lynch syndrome: a systematic review and meta-analysis.

The rationale behind complete mesocolic excision (CME) and a central vascular ligation for colon cancer in open and laparoscopic surgery : proceedings of a consensus conference.

P304

e99-e109

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/BJS.10756

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P50

Eva Morris

Philip Quirke

P5530

32148947

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1100457070

http://www.w3.org/2001/XMLSchema#string

P6366

2784918301

http://www.w3.org/2001/XMLSchema#string

P698

29341159

http://www.w3.org/2001/XMLSchema#string

P921

immunology

colorectal cancer